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reported outcomes (PROs) simultaneously following treatment with certolizumab 
pegol (CZP) 200 mg + methotrexate (MTX), in the RAPID 1 and RAPID 2 trials. 
METHODS: The proportions of patients reporting improvements ≥MCID in RAPID 
1 (Week 24 and Week 52) and RAPID 2 (Week 24) were determined for the following 
PROs: arthritis pain (0–100 mm visual analogue scale [VAS], MCID ≥ 10 mm), fatigue 
(Fatigue Assessment Scale, 0–10 numeric rating scale, MCID ≥ 1 point), physical 
function (Health Assessment Questionnaire-Disability Index, MCID ≥ 0.22 points), 
patient’s global assessment of disease activity (PtGA, 0–100 mm VAS, MCID ≥ 
10 mm), and HRQoL (SF-36 physical and mental component summaries [PCS, MCS], 
MCID ≥ 2.5 points). NNT to achieve improvements ≥MCID in at least 1, 2, 3, 4, 5, 
or 6 out of the 6 considered PROs simultaneously with CZP + MTX compared with 
PBO + MTX were also calculated. RAPID 1: NCT00152386; RAPID 2: NCT00160602. 
RESULTS: The NNT to report clinically meaningful improvements in up to 5/6 PROs 
following CZP + MTX treatment was very low; approximately 2–3 additional patients 
after 24 weeks (RAPID 1 and RAPID 2). The NNT remained similar at 52 weeks 
(RAPID 1). The NNT to report improvements in all 6 PROs was 5 additional patients. 
In patients who achieved MCIDs in at least 5 of 6 PROs by Week 52, clinically 
meaningful improvements were more likely to be reported in pain, fatigue, physical 
function and PtGA than SF-36 PCS or particularly MCS. CONCLUSIONS: Patients 
with active RA report meaningful and broad relief in PROs following treatment with 
CZP. The low NNTs indicate that few patients need to be treated with CZP + MTX 
to report relief from the multiple burdens of RA.
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OBJECTIVES: A Provincial prospective observational cohort study observes consecu-
tive Rheumatoid Arthritis (RA) patients starting anti-TNF therapy (inﬂ iximab, etan-
ercept or adalimumab). We aimed to assess the impact of switching anti-TNF agents 
at different time points. METHODS: Data in the registry is collected at baseline, 3 
months, and every 6 months thereafter up to 3 years on patients receiving anti-TNF 
agents. We grouped patients as inﬂ iximab or adalimumab starters, and etanercept 
starters. Health-related quality of life was measured with the EQ-5D and single index 
scores were calculated using US value sets. Clinical outcome measures assessed were 
the HAQ and DAS28 scores. We analyzed the mean EQ-5D index score, the HAQ 
score, and the DAS28 score over time within baseline starter groups according to the 
time of switch of treatment. RESULTS: From 1222 patients in the registry, 649 
patients had 27 months follow-up assessment and 76.7% remained on the ﬁ rst anti-
TNF. For these patients, signiﬁ cant improvement was observed by 3 months in the 
EQ-5D (mean change 0.296, P < 0.001), the HAQ (mean change −0.822, P < 0.001) 
and DAS28 (mean change −2.84 P < 0.001) that was sustained over the follow-up 
period. Those who switched at 3 months (primary failures) had signiﬁ cantly responded 
by the next measurement and the 27 months changes in outcomes were comparable 
to non-switchers (all P < 0.01). Patients who failed the ﬁ rst anti-TNF after the 3-month 
time point (secondary failures) obtained from 50% (HAQ) to 68% (EQ-5D) of the 
mean change compared to non-switchers (P < 0.05). Switching from Inﬂ iximab or 
adalimumab to etanercept or vice versa produced similar outcomes. CONCLUSIONS: 
The results show that primary failures to anti-TNF show similar responses to patients 
responding to their ﬁ rst anti-TNF agent. Secondary failures obtain about two-third of 
the outcomes compares to no-switchers and primary failures. Longer follow up is 
needed to see if the secondary failure patients can sustain the obtained 
improvement.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, disabling autoim-
mune disease. The ﬁ rst biologic drug (etanercept) for the treatment of RA was regis-
tered in 1998, the latest in 2009 (EMEA). Study design of randomized controlled trials 
(RCT) of RA has changed in the past years, specially in point of reducing the time on 
placebo. Our aim was to compare the efﬁ cacy, safety and tolerability of available 
biologic drugs and to review the challenges of comparing RA studies with different 
structures, taking the example of the lately registered drug certolizumab pegol. 
METHODS: Systematic literature search was performed (closed on 16.08.2009) for 
RCTs with minimum duration of 24 weeks, involving drugs that have been registered 
for the treatment of RA after traditional disease modifying drug failure. Improvement 
of symptoms by 20%, 50% and 70% (deﬁ ned by the American College of Rheumatol-
ogy, ACR), adverse events and withdrawals were considered as endpoints in the 
metaanalysis. RESULTS: Altogether 14 RCTs (adalimumab 3, certolizumab pegol 2, 
etanercept 2, inﬂ iximab 4, tocilizumab 2, golimumab 1) involving 6739 patients were 
selected for the analysis. Efﬁ cacy of certolizumab pegol was superior to other drugs 
at ACR20, 50 and 70 but heterogenity was observed at certain safety endpoints. 
Contrary to previous trials, patients on placebo not achieving ACR20 response at 
week 16 were withrawn in the certolizumab pegol studies. Thus patient number in 
the placebo group decreased dramatically for the remaining 8 weeks. To exclude this 
bias, we compared only the active arms and there was no signiﬁ cant difference in 
terms of safety and tolerability among the drugs. Analysis by patients years conﬁ rmed 
this ﬁ nding. CONCLUSIONS: Effectiveness and safety of recently registered biologic 
drugs in RA are similar to the previous agents. Differences in protocol of former and 
present RCTs should be carefully considered for the analysis.
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OBJECTIVES: Switching among tumor necrosis factor-α inhibitor (TNFi) agents or 
to another biologic is relatively common, but determinants of dose escalation are 
largely unknown. Among individuals who are escalating the dose from their ﬁ rst TNFi, 
we identiﬁ ed factors associated with the choice of dose escalation in a retrospective 
analysis of medical and pharmacy claims and eligibility data. METHODS: Eligible 
patients were ≥18 years of age, diagnosed with rheumatoid arthritis (RA, 2 diagnoses 
≥2 months apart) from January 2003–March 2008, had initiated a new TNFi prescrip-
tion after a 6-month biologic-free period and had at least 6 months of continuous 
enrollment. Kaplan-Meier (KM) analysis and Cox regression were used to analyze 
time to dose escalation. Multinomial logistic regression was used to determine factors 
affecting dose escalation. RESULTS: A total of 11,903 (6.9%) of 173,533 RA patients 
were identiﬁ ed. Among these patients, 16% (n = 1,903) after a mean of 261 days 
escalated their dose. Comorbidity scores, such as the severity index for rheumatoid 
arthritis (SIFRA) and Elixhauser, were higher for patients who escalated their dose. 
The likelihood of escalating the dose was increased by female sex, younger age, and 
baseline use of corticosteroids or cytotoxic agents. Baseline use of methotrexate raised 
the likelihood of dose escalation (relative risk ratio, 1.58). CONCLUSIONS: After 
initiating TNFi treatment, many RA patients failed to remain on therapy and escalated 
doses or switched to a second TNFi or another biologic ~1 year. Factors inﬂ uencing 
whether patients increased their dose included gender, age, and use of certain agents 
at initiation of the TNFi. a limitation of this study is that patients with <6 months of 
TNFi treatment were not included.
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OBJECTIVES: The aim of this study is to evaluate the occurrences of secundary hip 
and femur fractures according to its different risk factors with follow up 8 years. 
METHODS: In this retrospective study the data derive from the ﬁ nancial database of 
the Hungarian National Health Insurance Fund Administration, based on the 10th 
revision of the International Classiﬁ cation of Diseases (ICD) with ICD code S7200. 
The patients included into the study had femur neck fracture and being discharged 
from the hospital after the primary treatment in 2000. The patients with polytrauma 
were excluded from the study. We evaluated data according to sex, age, type of 
fracture, type of surgery, local complications, type of residence. RESULTS: A total of 
3783 patients met selection criteria of primary femoral neck fracture. During the 
postoperative 8 years 347 patents (9,2%) had secondary hip and femur fractures. 
Average age of patient with primary hip fracture 78 years, with secundary hip fracture 
80,6 years. We demonstrated the following incidence rate of secundary hip fractures 
according to risk factors: Sex: female: 10,3%, male: 5,8%. Age groups: 60–69 y: 
5,3%, 70–79 y: 7,5%, 80–89 y: 12,4%, 90 y-: 14,1%. Type of fracture: lateral: 6,9%, 
medial 9,5%. Type of surgery: osteosynthesis: 8,5%, arthroplasty: 13,6%. Local 
complications: yes: 10,6% no: 9%. Type of residence: capital 11,5%, village: 7,9%, 
city: 10%, town: 8,2%. CONCLUSIONS: The secondary hip fracture rate increased 
with the age of patients. The secondary hip fracture rate was the highest in female, in 
patient with primary intracapsular femoral neck fracture, after arthroplasty, in patient 
with local complication, in patient with capital residence. Many other factors can 
inﬂ uence this secondary hip fractur, which will be analyzed in our further studies.
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OBJECTIVES: The primary aim of this study was to assess the incidence of hip 
fractures in Belgium between 2000 and 2007 and to examine secular changes within 
this period. a secondary aim was to estimate the expected number of hip fractures in 
Belgium until 2050. METHODS: The incidence of hip fractures was determined using 
the national database of hospital bills, which fully cover the annual hospital stays in 
the whole of the country. Population data and projections were derived from ofﬁ cial 
sources. Logistic regression including year and age classes was performed for both 
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genders to assess the secular change between 2000–2002 and 2005–2007. Hip fracture 
projections were made until 2050, assuming the gender-speciﬁ c secular change 
observed between 2000–2007 will be maintained. RESULTS: A total of 113,101 hip 
fractures were recorded in Belgium between 2000 and 2007, of which 76.4% occured 
in women. The annual number of hip fractures increased from 13,512 in 2000 to 
14,744 in 2007, with a more marked increase in men (+20.4%) than in women 
(+5.7%). Between 2000–2002 and 2005–2007, the age-adjusted incidence of hip 
fractures signiﬁ cantly decreased by 1.08% per year (95% CI: 0.78 to 1.38) in women, 
but declined non-signiﬁ cantly by 0.30% per year (95% CI: −0.24 to 0.84) in men. 
The female/male ratio of hip fractures decreased between these periods from 3.19 to 
2.92 (P < 0.01). By the year 2050, the number of hip fractures is expected to increase 
by 37.8% in women and by 110.0% in men. The female/male ratio would decrease 
to 1.81. CONCLUSIONS: Despite a signiﬁ cant decrease in the age-adjusted incidence 
of hip fractures in Belgian women and a non-signiﬁ cant decline in men, the number 
of hip fractures is expected to substantially increase in Belgium. Appropriate public 
health strategies are therefore needed and should also focus on populations of men.
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OBJECTIVES: While the disease burden of gout in the US has been considered sub-
stantial and may have been rising over the past decade, no contemporary national 
data are available. We estimated the prevalence of gout based on a recent, nationally 
representative sample of US men and women (National Health and Nutrition Exami-
nation Survey [NHANES] 2007–8). METHODS: Using data from 5707 participants 
in NHANES 2007–8 (2797 men and 2910 women) aged ≥20 years, we estimated 
overall, gender-speciﬁ c, and age-speciﬁ c prevalence of gout. During the home inter-
view of NHANES, all participants were asked: “Has a doctor or other health profes-
sional ever told you that you had gout?” We estimated the number of individuals with 
gout by applying our prevalence estimates to the corresponding 2008 US population 
estimate of 214.8 million adults over age 18. RESULTS: Overall prevalence of gout 
among US adults was 3.9%, which corresponded to an estimated 8.3 million individu-
als with gout. Prevalence of gout was 5.9% (6.1 million) among men and 2.0% (2.2 
million) among women. Prevalence of gout increased with age, with the lowest (0.4%, 
0.2 million) in those aged 20–29 years and the highest (12.6%, 1.2 million) in those 
aged ≥80 years. Prevalence of gout among those aged <64 years was 2.7% and was 
higher (9.8%) among those aged ≥65 years. Those ≥65 years corresponded to an 
estimated 3.5 million adults with gout. CONCLUSIONS: These ﬁ ndings from the 
latest nationally representative sample of US adults in NHANES 2007–2008 suggest 
that the prevalence of gout is substantial, particularly among older (aged ≥65 years) 
individuals. Additional conﬁ rmation studies are needed.
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OBJECTIVES: The main goals of this retrospective study were to analyze the Preva-
lence of Gout in GPs ofﬁ ces in Italy and to describe the management of gouty patients 
by the GPs in terms of types and number of Specialistic visits requests during 12 
months of follow-up. METHODS: Data were obtained from CSD LPD, a General 
Practitioner’s longitudinal database. Patients with at least one diagnosis of Gout from 
January 2008 to December 2008 have been selected and followed-up for 12 months. 
RESULTS: From 1.126.847 active patients, 17.241 had at least one diagnosis of gout, 
resulting on a prevalence of 1.53% in the general population. Among the 17.241 
patients only 1.42% had received a specialistic visit request related to gout; of these 
the 42.8% were Reumatology visit requests, the 20.4% Ortopedics visits, the 8.1% 
Nephrology visits. Comparing the group of patients with at least one visit request 
related to gout (244) to the rest of the patients (16.997) in terms of specialistic visits 
request (related to all kind of diagnosis) during follow-up period, it could be seen that 
the group of 244 patients had received in average 4.5 specialistic visits request while 
the rest of the patients had received 2.3 visit requests. CONCLUSIONS: During the 
study we have identiﬁ ed a group of patients (244 patients 1,4% of the total) with at 
least one specialistic visit request related to the diagnosis of Gout, and we assumed 
that this group represents “Complicated patients” , maybe refractory to the therapy, 
that GPs need to manage in cooperation with specialist physicians. On support of our 
hypothesis the average number of specialistic visits (related to all kind of diagnosis) 
among this group is signiﬁ catively higher in comparison with the rest of the patients 
(4.5 vs. 2.3).
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OBJECTIVES: Recent trends in the number of primary total hip arthroplasty (THA) 
and total knee arthroplasty (TKA) in the US has suggested a massive future demand 
for THA and TKA. It is unknown if this trend is the same in France as France has a 
slower growth rates in obesity compared to US. The purpose of our study was to 
describe the recent trend of primary THA and TKA in France. METHODS: Registry 
data on THA and TKA, collected between 2000 and 2006, were obtained from the 
Agence technique de l’information sur l’hospitalisation (ATIF 2009). RESULTS: In 
2006, approximately 139,000 hip replacements and 66,000 knee replacements were 
performed in France. Hip procedures increased by 6% and knee procedures by 30% 
since 2001. The economic burden associated with joint replacements is estimated 
approx. 2 billion Euro in 2006. The mean cost for primary hip replacement in France 
was c7,467 in 2006 and c8,690 for knee replacement procedures. Arthroplasties 
represent the medical specialty with the highest expenses in France. In France, only 
41% of knee replacements were cemented. This proportion is relatively low in com-
parison to others European countries. CONCLUSIONS: This trend could accelerate 
in the near future due to changes in French demographics: increase of prevalence of 
overweight and obese patients as well as population ageing. These two categories of 
population have the highest incidence of joint replacement procedures. Obesity preva-
lence increases by 5% every year since 1997 to reach 12.4% of the total population 
in 2006 and the elderly population will reach 30% of the French population by 2050. 
In the context of the current ﬁ nancial crisis reducing unnecessary health care expen-
diture is inevitable. In the French market implant price represent 30% of hip replace-
ment procedure and 38% for knee replacement.
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OBJECTIVES: The number of primary total hip arthroplasties (THAs) and total knee 
arthroplasties (TKAs) continues to increase steeply in the US. It is unknown if this 
trend is the same in Germany and the United Kingdom (UK) as these populations age 
and become heavier. The purpose of our study was to investigate recent trends of 
primary THA and TKA in Germany and the UK. METHODS: We analyzed data from 
the German Bundesgeschäftsstelle für Qualitätssicherung and the UK’s National Joint 
Register. RESULTS: Between 2004 and 2008 in Germany, THAs increased 14% and 
TKAs increased 32%. During the same time in the UK, there were 60% and 70% 
increases in THAs and TKAs, respectively. In the UK, more TKAs than THAs have 
been performed since 2005, and a similar trend is expected in Germany after 2010. 
Nearly 20% of TKAs in Germany were performed on non-elderly patients (64 or 
younger) and patient age distributions remained approximately the same over the 
study period. In the UK, however, approximately 30% of TKAs were on non-elderly 
patients and the proportion of non-elderly patients that underwent TKA has increased 
every year. CONCLUSIONS: The number of arthroplasties in the US has increased 
dramatically among non-elderly adults. We observed no increase in this patient group 
in Germany but a slow and gradual increase in the UK. As obesity has risen over the 
last decades, the US has experienced greater inclines in TKAs than THAs; the annual 
number of TKAs is now twice that of THAs. Although the number of TKAs and the 
number of THAs had been approximately the same in Germany and the UK, recent 
trends suggest a growing gap due to a steeper rise in TKAs. Obesity, a strong risk 
factor for TKA, may be a bigger contributor than aging to the recent growth in joint 
arthroplasty.
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OBJECTIVES: The aim of this study was to elucidate the incidence of recurrent 
fractures and the current status of osteoporosis treatment within one year after the 
ﬁ rst hip fracture. METHODS: This study was conducted for all female patients who 
were 65 years or older who had experienced hip fracture due to trauma for the ﬁ rst 
time and were treated within ﬁ ve geographic areas in Japan during the study period 
(January 2006 to December 2007). The data on demographics, treatments, and health 
outcomes were collected from medical records. a patient questionnaire was mailed to 
every patient about the health outcomes. RESULTS: The analysis was conducted in 
2330 patients (average age 83.6 years). During the one-year observational period 158 
fractures occurred in 152 patients. The incidence for all fractures among patients with 
ﬁ rst hip fracture was 71.7 (per 1000 person-year), and that for hip fracture was 36.7. 
The relative risk of recurrent hip fracture was 4.4 for women aged 65 years and over 
with ﬁ rst hip fracture. During this one-year period, anti-osteoporosis pharmacother-
apy was performed in 437 patients (18.8%) while 1240 patients (53.2%) received no 
treatment. CONCLUSIONS: This study demonstrated the high risk of recurrent 
fracture in patients with ﬁ rst hip fracture and inadequate treatment for fracture pre-
vention after ﬁ rst hip fracture. Since hip fracture patients are the most plausible 
candidates in the prevention of recurrent fractures, especially second hip fractures with 
high burden, appropriate treatment of osteoporosis is essential.
